Ensuring Timely Access to Generics Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
Tightens FDA citizen-petition procedures to make it harder to use petitions and related litigation to delay approval of generic or biosimilar products.
Who Benefits and How
Generic and biosimilar applicants could face fewer delay tactics based on late or repetitive petitions and related lawsuits.
Who Bears the Burden and How
Petitioners, including brand-drug interests, would face earlier filing deadlines, exhaustion requirements, and stricter dismissal rules in court.
Key Provisions
- Expands the factors FDA may consider when determining whether a petition was submitted primarily to delay an application.
- Requires petitions to be filed before related civil actions and generally within 180 days after the filer knew the underlying information.
- Requires courts to dismiss certain actions that bypass or miss the petition process.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Tightens FDA citizen-petition procedures to make it harder to use petitions and related litigation to delay approval of generic or biosimilar products.
Key Policy Areas
Healthcare, Government Operations
Primary Purpose
Tightens FDA citizen-petition procedures to make it harder to use petitions and related litigation to delay approval of generic or biosimilar products.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- Generic and biosimilar applicants facing fewer petition-based delay tactics
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Petitioners and litigants seeking to use citizen petitions to delay FDA approvals
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeMrs. Shaheen (for herself and Ms. Collins) introduced the following …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Generic and biosimilar applicants facing fewer petition-based delay tactics, Petitioners and litigants seeking to use citizen petitions to delay FDA approvals
Positive-direction: Generic and biosimilar applicants facing fewer petition-based delay tactics
Negative-direction: Petitioners and litigants seeking to use citizen petitions to delay FDA approvals
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology